The 30 questions people ask before they start

BPC-157 is the typical entry point, with a conservative dose of 250 micrograms subcutaneously per day, 5 days on and 2 days off. The mechanism is angiogenic and nitric-oxide-driven, the safety record in early human trials is clean, and the indications cover gut, tendon, ligament, and connective tissue in a single peptide. If the goal is sleep-led recovery rather than injury repair, the entry point is more often a growth hormone secretagogue such as ipamorelin at 100 micrograms at bedtime.

This is the first question any prescribing clinician will ask. BPC-157, TB-500, and the growth hormone secretagogues all have angiogenic activity and can interact with anticoagulants, antihypertensives, and thyroid replacement. The published safety data in these combinations is thin. Work with a prescriber who can monitor INR, blood pressure, and IGF-1, and who knows which peptides to avoid in your specific medication list.

Yes. IGF-1, fasting glucose, HbA1c, full thyroid panel, liver enzymes, kidney function, lipid panel, and a baseline PSA for men are a sensible starting panel. The angiogenic peptides and the GH secretagogues all interact with these markers, and you need a baseline to compare against. A complete blood count and a metabolic panel catch most of the safety signals you would worry about.

Soft tissue and joint repair takes 4 to 8 weeks of consistent use. Sleep and energy shifts from growth hormone secretagogues can show up in the first week. Visible skin and hair shifts from GHK-Cu take 6 to 12 weeks. Cognitive and mitochondrial effects take longer to assess and are easier to miss without objective measures.

Practitioners working with this age group tend to converge on three or four peptides: BPC-157 for connective tissue and gut repair, ipamorelin or sermorelin for sleep and recovery, thymosin alpha-1 for immune modulation, and GHK-Cu for skin, hair, and gene-expression support. MOTS-c is added if metabolic and exercise capacity is a priority. None of this is approved for the ageing indication.

No. Cartilage has limited blood supply and limited intrinsic regenerative capacity. BPC-157 improves the conditions around the joint (blood flow, inflammation, tendon insertion, synovial response) but does not regrow cartilage. The realistic outcome is reduced pain, better function, and slower further degeneration. For severe osteoarthritis, the surgical conversation is the realistic one.

BPC-157 is angiogenic and works through the nitric-oxide system. TB-500 (thymosin beta-4 fragment) works through actin sequestration and cell migration, with broader systemic distribution. Practitioners often stack them during a defined injury phase: BPC-157 daily near the injury, TB-500 twice weekly for 4 to 6 weeks, then taper.

No. The soft tissue, scar tissue, and muscle around a healed joint replacement respond to the same repair pathways as native tissue. BPC-157, TB-500, and GHK-Cu can all be useful in this setting. The caveat is that peptides will not address a failing implant, a loose prosthesis, or infection. Those are surgical conversations.

Most practitioners run a defined injury course of 6 to 12 weeks, then stop and reassess. Long-term continuous use is uncommon in the practitioner literature for any of the repair peptides. Some older patients run low-dose BPC-157 (250 mcg, twice weekly) for chronic joint maintenance, but this is off the standard cycle.

Two paths. Ipamorelin at 100 micrograms at bedtime on an empty stomach is the standard practitioner entry point. It produces a single clean growth hormone pulse without cortisol or prolactin co-release. Sermorelin is the alternative, with a wider dose range (200 to 1,000 micrograms) and a long clinical track record. Both are 5 nights on, 2 off, in 12-week blocks with 4 weeks off to prevent receptor desensitisation.

Yes, in principle. Pinealon is a peptide often stacked with oral melatonin, on the logic that pinealon supports the pineal gland's natural melatonin output while exogenous melatonin covers the immediate shortfall. The pinealon evidence is Russian and not replicated in Western trials, so treat it as adjunct rather than primary.

Often no. Common drivers in this age group are anaemia (low ferritin and B12), obstructive sleep apnoea, suboptimal thyroid, low-grade inflammation, and medications. Get those ruled out before adding a peptide. If the workup is clean and the issue is genuinely growth-hormone-related, ipamorelin or a CJC-1295 + ipamorelin stack is the next conversation.

Modestly, with two conditions. The growth hormone pulse has to be paired with resistance training and adequate protein (around 1.6 g/kg/day). Without the training stimulus, the secretagogue moves recovery and sleep but not muscle mass. With the stimulus, you can see 1 to 2 kg of lean mass over 12 to 16 weeks in a previously untrained older adult, which is meaningful for fall risk and independence.

MOTS-c is the most evidence-supported mitochondrial peptide for muscle and metabolic function in older adults, based on the work from Pinchas Cohen's group at USC. The effect is exercise-mimetic, so it works best alongside training. Dosing in practitioner protocols is 5 to 10 milligrams subcutaneously, 3 to 5 times per week, in 8 to 12 week cycles. The human outcome data is still early.

If the goal is muscle anabolism specifically, the strongest case is for growth hormone secretagogues plus training, or for retatrutide if the underlying issue is obesity-driven muscle loss. BPC-157 supports connective tissue so training is possible. Thymosin alpha-1 supports the immune system so training is not interrupted by illness. There is no peptide that builds muscle on its own without stimulus and protein.

The angiogenic peptides (BPC-157, TB-500, GHK-Cu) deserve a careful conversation with a cardiologist before use in anyone with active atherosclerosis, unstable plaque, or a recent thrombotic event. The growth hormone secretagogues raise IGF-1, which is a long-term cancer surveillance consideration. MOTS-c is metabolic and may be appropriate. Epitalon has telomerase activity and is not well studied in this population.

Two paths. MOTS-c has the cleanest metabolic and insulin-sensitivity mechanism, based on rodent work and human pharmacokinetics. Retatrutide and tirzepatide have the strongest human weight loss and glucose-lowering data. For prediabetes without obesity, MOTS-c plus dietary intervention is the more conservative first move. For obesity-driven glucose drift, an incretin is the more evidence-supported choice.

The peptides with mechanistic interest here are BPC-157 (angiogenic and endothelial-supporting), MOTS-c (metabolic flexibility), and GHK-Cu (gene-expression support for connective tissue). None of these are approved for atherosclerosis. The honest answer is that statin therapy, blood pressure control, and exercise have the strongest evidence base, with peptides as adjuncts at best.

Thymosin alpha-1 is the best-supported immune-modulating peptide in the field, with thirty years of clinical safety data outside the US and an established use case in chronic viral illness and immune senescence. The dose is 1.6 to 5 milligrams subcutaneously per day, 5 days on and 2 off, in 4 to 8 week blocks. Worth a conversation with a prescriber if recurrent infection is a real issue.

The relevant immune-modulating peptides are thymosin alpha-1 for the immune dysregulation, BPC-157 for the endothelial and fatigue components, and MOTS-c for the metabolic and exercise-capacity components. None are approved for long COVID, and the practitioner experience is the only evidence base. The general inflammatory, sleep, and metabolic supports are also relevant.

The relevant peptides are selank and semax (both Russian-developed and available in nasal spray form), cerebrolysin (a porcine brain peptide mixture used in stroke and TBI recovery), and GHK-Cu (gene-expression support). The evidence base is mixed. The most defensible move is aggressive lifestyle work (sleep, exercise, blood pressure, glucose control, hearing, social engagement) plus a trial of one peptide with objective baseline measures. If the issue is a defined neurodegenerative disease, the conversation belongs in a memory clinic.

BPC-157 and the growth hormone secretagogues can interact with antihypertensives and anticoagulants. Cerebrolysin can interact with antidepressants. Most other peptides in the field have a cleaner interaction profile, but the published data is thin for an older adult on multiple medications. The rule is to bring a list of every medication and supplement to the prescribing clinician and let them assess the combinations.

Topical GHK-Cu at 1 to 3 percent in a serum, applied morning and night, has the best evidence for skin firmness, elasticity, and fine lines. Hair response is slower and less consistent. Injectable GHK-Cu at 1 to 2 milligrams subcutaneously per day is a recent practitioner addition for systemic gene-expression effects, but the data is mechanistic plus case series, not RCT.

For most indications, yes, in the sense that the side-effect profile is small relative to fillers, botulinum toxin, and laser work. They are not a replacement for sunscreen, retinoids, and the basics, but they layer onto those well.

PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is used off-label in men. Dose is 0.5 to 2 milligrams subcutaneously, 45 to 60 minutes before activity, no more than once in 24 hours and no more than 8 doses per month. Nausea is the main side effect, and the response is reliable in both sexes. The melanocortin mechanism works centrally and is unaffected by PDE-5 inhibitors, so the two can be combined for men with both desire and erection issues.

PT-141 covers the central desire and arousal side. The vascular and tissue-trophic side of erectile function responds to GH secretagogues plus the standard cardiovascular work. Vaginal tissue thinning in post-menopausal women responds to local oestrogen and DHEA, which are not peptides, and to GHK-Cu in topical compounded formulations. There is no peptide that is a direct replacement for local oestrogen in this setting.

The short answer is that the US compounding peptide market is uneven, and the 2023 FDA decision to remove several peptides from the 503A bulk substance list reshaped the supply chain. Workarounds such as PDA and modified BPC variants have appeared without a published safety record. The practitioner minimum is third-party HPLC and mass spectrometry testing of each batch, and a sourcing relationship that can show a certificate of analysis.

Red flags include no third-party testing offered, no certificate of analysis on request, prices that are dramatically below the compounding pharmacy norm, and peptides sold as research chemicals with no medical oversight. The reputable path is a US-based 503A or 503B compounding pharmacy with a physician's prescription, or a clinician who sources from one.

The angiogenic peptides (BPC-157, TB-500, GHK-Cu) and the growth hormone secretagogues (which raise IGF-1) all carry theoretical tumour-promotion concerns. The actual data is mixed, but the conservative path is to avoid these classes in anyone with active cancer or a recent cancer history, and to discuss each one with an oncologist if there is a defined past history.

Modestly. The growth hormone secretagogues and the angiogenic peptides are not directly contraindicated, but PSA monitoring should be in place. The bigger practical issue is that PT-141 can cause transient blood pressure changes and is best used at a lower starting dose (0.5 to 1 milligram) in this age group.

None of the common practitioner peptides are heavily renally cleared, so most are usable in reduced kidney function at standard doses. BPC-157 has the cleanest profile in this regard. The peptides to be most cautious with are the ones you cannot dose accurately due to small volume (high-concentration solutions are hard on a syringe, and the dosing errors compound in anyone with reduced manual dexterity).

The honest answer is that the data is thin for most of them. BPC-157 and the growth hormone secretagogues are most often cycled, not run continuously. Thymosin alpha-1 is commonly pulsed. GHK-Cu topical is safe for continuous use. MOTS-c and the cognitive peptides are early enough that nobody has long-term outcome data in healthy older adults. Work with a prescriber who is willing to reassess every 6 to 12 months.

The short pulses from ipamorelin, sermorelin, and CJC-1295 do not suppress endogenous growth hormone production the way continuous exogenous growth hormone does. The receptor desensitisation risk is real (which is the reason cycling matters) but the negative-feedback suppression that exogenous HGH causes is not the same issue. The longer-term data in older adults is still limited, so this is a thing to watch, not a thing to assume is settled.

Peptides can support recovery, sleep, immune function, lean mass with training, and connective tissue repair. They cannot reverse sarcopenia on their own, reverse atherosclerosis, regrow cartilage, or substitute for the lifestyle factors that move the major age-related outcomes. The honest framing is that they are one tool in a stack of interventions, with the others being exercise, sleep, protein, cardiovascular risk control, social engagement, and the standard screening protocols.

Bring the field reference, the dosing calculator, and the specific protocol you are considering. Most prescribers are willing to supervise a reasonable protocol if the patient does the homework and the workup is in place. The peptides that fall outside the prescriber's comfort zone are best handled by a clinician who has specific peptide-medicine experience.

Thymosin alpha-1 for immune modulation in older adults, and semaglutide or tirzepatide for weight and metabolic control. Both have decades of clinical safety data, approved indications in adjacent populations, and well-understood risk profiles. If a person is going to start with one FDA-tractable peptide, one of these is the most defensible choice.

Peptides are real drugs with real biology, not magic. Some have FDA approval for specific indications, and the evidence in healthy older adults is mostly mechanistic and small-cohort. The honest position is that they are best used as adjuncts to the things that move the major outcomes (exercise, sleep, blood pressure, glucose, lipids, cancer screening), that they should be sourced from a compounding pharmacy with third-party testing, and that they should be supervised by a clinician who is willing to monitor bloodwork.